ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / FTH / insiders
EOLS (26) AQST (18) MPLT (35) INDP (42) ⌘ Pro Terminal →

Faeth Therapeutics Inc. (FTH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$19.23 +2.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.29

Faeth Therapeutics Inc. (FTH) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $483.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FTH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Faeth Therapeutics Inc. (NASDAQ: FTH) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $19.23 (+2.89% 1D, market cap $483.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1016 tracked Health Care issuers, FTH ranks #858 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FTH compare to EOLS and AQST in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FTH carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EOLS (Evolus Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $485.5M) and AQST (Aquestive Therapeutics Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $488.2M). Among the 5-stock peer group, FTH leads on earnings multiple (N/A) while MPLT leads on capital efficiency (-32.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FTH?
▼

Per FTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001829802), Faeth Therapeutics Inc. generated $62.4M in revenue (-31.7% YoY), -$21.1M in net income, and -$20.5M in free cash flow against $22.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $19.29 (+0.33%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (3)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.5% Base Target
$44 Bull$17 Base$13 Bear
📬 FREE FTH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FTH)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY FTH SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (36% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$21.51-3.3% Next Q
Q2 (-2Q)
33
Grade E$20.79-8.1% Next Q
Q3 (-1Q)
31
Grade E$19.11+0.6% Next Q
Current
28
Grade E$19.23-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FTH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FTH currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($28.22) and Max Pain ($20.19) forces dealer call-delta covering toward $44.25.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FTH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FTH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

FTH Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (FTH)

No recent open-market Form 4 cluster sales or emergency dumps flagged on FTH. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FTH)

  • ✓Walkthrough of FTH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
FTH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.98%📐 HORIZONTAL RANGE
2026-11-03O $18.75H $19.23L $18.69C $19.23VOL 511.0K
RES: $46.38SUP: $15.89SMA50: $28.22SMA200: $25.22
$44.34$35.24$26.15$17.05$7.96RES $46.38SUP $15.89$19.232026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FTH Butterfly Map → + Track FTH →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -31.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FTH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FTH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FTH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FTH)

Health Care Rank #858 of 1016 ⚔️ EOLS vs FTH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FTH vs. EOLS, AQST, MPLT, INDP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Faeth Therapeutics Inc. (FTH) ranks #858 by composite RQD confidence (28/100, grade E) and #452 by equity capitalization ($483.0M). Within this direct 5-issuer industry benchmark cohort, FTH leads on earnings valuation at N/A trailing P/E, while MPLT leads on capital efficiency and profitability with -32.4% ROIC and — gross margin. INDP currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with FTH at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FTH ACTIVE
Faeth Therapeutics Inc.
E 28/100 — — -35.0% +2.89% $483.0M Benchmark Subject
EOLS
Evolus Inc.
E 26/100 — 66.3% -35.0% -2.58% $485.5M /eols-vs-fth →
AQST
Aquestive Therapeutics Inc.
E 18/100 — 58.3% -35.0% -3.08% $488.2M /aqst-vs-fth →
MPLT
MapLight Therapeutics Inc.
D- 35/100 — — -32.4% -10.55% $491.0M /mplt-vs-fth →
INDP
Indaptus Therapeutics Inc.
D- 42/100 — — -35.0% +13.27% $474.6M /indp-vs-fth →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001829802 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Faeth Therapeutics Inc. (FTH) reported GAAP revenue of $62.4M (-31.7% vs. FY2024 revenue of $91.3M , and -39.9% cumulative change since FY2023) , GAAP net income of -$21.1M, operating cash flow of -$20.5M, and free cash flow of -$20.5M (+17.5% YoY). On the balance sheet, FTH closed FY2025 with $22.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $62.4M -$21.1M -$20.5M -$20.5M $22.9M —
FY2024 (FY) 2024-12-31 $91.3M -$30.2M -$24.7M -$24.8M $45.4M —
FY2023 (FY) 2023-12-31 $103.8M -$34.1M -$32.0M -$32.0M — —

3. FTH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Faeth Therapeutics Inc. (NASDAQ: FTH) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $19.23 (+2.89% 1D, market cap $483.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1016 tracked Health Care issuers, FTH ranks #858 in composite RQD confidence.

How does FTH compare to EOLS and AQST in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FTH carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EOLS (Evolus Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $485.5M) and AQST (Aquestive Therapeutics Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $488.2M). Among the 5-stock peer group, FTH leads on earnings multiple (N/A) while MPLT leads on capital efficiency (-32.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FTH?

Per FTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001829802), Faeth Therapeutics Inc. generated $62.4M in revenue (-31.7% YoY), -$21.1M in net income, and -$20.5M in free cash flow against $22.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FTH trading relative to its 50-day, 200-day, and 52-week technical levels?

FTH last traded at $19.23 (+2.89% on volume of 212,615 shares), positioning the stock -31.86% below its 50-day simple moving average ($28.22) and -23.75% below its 200-day simple moving average ($25.22). Across its 52-week range of $7.45 to $42.14, FTH sits at the 34.0% percentile with a 14-day RSI of 34.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($16.83 to $21.63).

Direct Sub-Reports: FTH RQD Cockpit FTH 12M Forecast FTH Earnings & Move FTH Dividends & DRIP FTH Insiders & 13F FTH Whale Options FTH Profit Sankey FTH News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

FTH — Faeth Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Faeth Therapeutics Inc. (FTH) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $19.23 (+2.89% 1D, market capitalization $483.0M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -4.22%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Faeth Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — across the periods provided, indicating no revenue generation in those years.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Faeth Therapeutics Inc. (FTH) reported $62.4M in annual revenue (up from $91.3M in FY2024, -31.7% YoY) and -$21.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($103.8M revenue, -$34.1M net income) through FY2025, FTH scaled operating cash flow to -$20.5M and free cash flow to -$20.5M, backed by $22.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -4.22% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $7.45 – $42.14 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context is that FTH sits in Health Care / Biotechnology: Pharmaceutical Preparations, and a prospective investor should note that the absence of mapped links means the graph cannot identify ripple effects from partners, suppliers, or customers.

  • Key Question #1: Can FTH sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $62.4M and free cash flow of -$20.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is FTH's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

FTH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Faeth Therapeutics Inc. (FTH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FTH Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FTH Bull vs. Bear Conversation Board — What's Your Call at $19.23?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FTH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FTH:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $23.18 (+24.0%)
📌 Pinned Debate

The stock trades at $18.75, well above its $7.45 52-week low, and the company's operating losses narrowed from -$37.1M in FY 2023 to $-

Here is why I am bullish on FTH here at $18.69: The stock trades at $18.75, well above its $7.45 52-week low, and the company's operating losses narrowed from -$37.1M in FY 2023 to -$22.3M in FY 2025.. Compare FTH's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $17.76 are getting bought.

VolSurface_Trader 🐂 BULL

@CreditSpread_Watch Shorting a 3/20 institutional whale-flow stock at $18.69 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $14.95 (-20.0%)
Spot @ $18.69

With ROIC at -35%, FCF of -$20.5M in FY 2025 against only $8.7M of reported cash, and an RQD score of 29 with an E grade, the fundament

With ROIC at -35%, FCF of -$20.5M in FY 2025 against only $8.7M of reported cash, and an RQD score of 29 with an E grade, the fundamentals show limited cash runway and weak forensic quality.. Look at the math on FTH: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $16.45 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%